Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region

Tomioka, Nobumoto; Hatanaka, Kanako C.; Okuyama, Dai; Watanabe, Ken-ichi; Yamamoto, Mitsugu; Maeda, Hideki; Tachikawa, Hanae; Kuwahara, Sayuri; Shimizu, Ai; Suzuki, Hiroaki; Hatanaka, Yutaka; Takahashi, Masato

Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region

Tomioka, Nobumoto; Hatanaka, Kanako C.; Okuyama, Dai et al.

Breast cancer, 2023, 30(3), 497-505

Permalink : https://hdl.handle.net/2115/89178

このアイテムのアクセス数:286件（2026-08-19 01:45 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.1007/s12282-023-01442-9			16

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/89178
タイトル	Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region
著者	Tomioka, Nobumoto ; Hatanaka, Kanako C. ; Okuyama, Dai ; Watanabe, Ken-ichi ; Yamamoto, Mitsugu ; Maeda, Hideki ; Tachikawa, Hanae ; Kuwahara, Sayuri ; Shimizu, Ai ; Suzuki, Hiroaki ; Hatanaka, Yutaka ; Takahashi, Masato
著者名 Tomioka, Nobumoto
著者名 Hatanaka, Kanako C.
著者名 Okuyama, Dai
著者名 Watanabe, Ken-ichi
著者名 Yamamoto, Mitsugu
著者名 Maeda, Hideki
著者名 Tachikawa, Hanae
著者名 Kuwahara, Sayuri
著者名 Shimizu, Ai
著者名 Suzuki, Hiroaki
著者名 Hatanaka, Yutaka
著者名 Takahashi, Masato
言語	英語
キーワード	PD-L1
	TILs
	TNBC
	TME
	ICI
発行日	2023-05-01
出版者	Springer
収録物名	Breast cancer
巻(号)	30(3)
ページ	497-505
抄録	BackgroundThe efficacy of pre-operative systemic treatment (PST) combined with immune checkpoint inhibition (ICI) for triple-negative breast cancer (TNBC) has been recognized recently as being independent of the degree of programmed death ligand-1 (PD-L1) positivity of infiltrating immune cells, especially for patients with axillary lymph node metastasis (ALNM).MethodsTNBC patients with ALNM were treated surgically between 2002 and 2016 in our facility (n = 109), of whom 38 received PST before resection. The presence of tumor-infiltrating lymphocytes (TILs) expressing CD3, CD8, CD68, PD-L1 (detected by antibody SP142) and FOXP3 at primary and metastatic LN sites was quantified.ResultsThe size of invasive tumor and the number of metastatic axillary LN were confirmed as prognostic markers. The numbers of both CD8+ and FOXP3+ TILs at primary sites were also recognized as prognostic markers, especially for overall survival (OS) (CD8, p = 0.026; FOXP3, p < 0.001). The presence of CD8+, FOXP3+ and PD-L1+ cells was better maintained in LN after PST and may contribute to improved antitumor immunity. Provided they were present as clusters of >= 70 positive cells, even < 1% of immune cells expressing PD-L1 at primary sites predicted a more favorable prognosis for both disease-free survival (DFS) (p = 0.004) and OS (p = 0.020). This was the case not only for 30 matched surgical patients, but also in all 71 surgical only patients (DFS: p < 0.001 and OS: p = 0.002).ConclusionsPD-L1+ , CD8+ or FOXP3+ immune cells in the tumor microenvironment (TME) at both primary and metastatic sites are significant on prognosis, which could be a clue to expect the potential for better responses to the combination of chemotherapy and ICI, especially for patients with ALNM.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
PISSN	1340-6868
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1007/s12282-023-01442-9